AIM-HIV PROJECT------------------------Instituto Salud Carlos III



The Spanish Institute of Health Carlos III (ISCIII), from the Ministry of Health, is the equivalent in Spain to the American Centers for Diseases Control. National Center for Microbiology is the reference for infectious diseases in the country. It has responsibilities in basic and clinical research, epidemiological surveillance and control of outbreaks including emergent diseases. More than 500 workers collaborate directly in these tasks at the National Centre of Microbiology. The center has equipped laboratories of molecular biology, cell culture and access to centralized facilities including genomics, conventional and ultra-deep sequencing, proteomics, confocal microscopy, flow cytometry, animal facility and BL3 laboratories. The main focus of research for more than 15 years has been HIV pathogenesis, in particular the mechanisms involved in HIV latency and reactivation and viral entry. In these fields ISCIII has identified new cellular factors maintaining HIV latency and driving viral reactivation. Besides, evolution of the viral envelope along infection and its interaction with the viral receptors has been addressed using new mass-sequencing technologies. Recently, in collaboration with Pasteur Institute, Hôpital St Louis and the French National Genotyping Centre, ISCIII is addressing the study of new cellular factors involved in HIV restriction. In parallel with these basic-science approaches, an intense translational activity has been developed by the AIDS Immunopathogenesis Unit to built-up a platform based on the recombinant virus technology licensed by the group that allows the study of resistance to antiretrovirals, screening and characterisation of the mechanism of action of new compounds and the assessment of viral tropism and titration of neutralizing antibodies. This technology will be extremely useful to assess the antiviral profile of 5HT against different HIV-1 strains.

Project coordinator Dr. Alcamí has a broad experience in the development and management of cooperative projects with national and international partners supporting his role in this project.


The French Atomic Energy and Alternative Energies Commission (CEA) employs 15.300 people and is active in three main fields — energy, information and health technologies, and defence and national security —from fundamental to technological research. The Life Science Directorate is in charge of health research and related technologies. The Institute of Emerging Diseases and Innovative Therapies (iMETI), hosting the Division of Immuno-Virology Partner (DIV) of this project, is one of the eight institutes managed by this directorate. DIV has acquired strong expertise and skills (more than 15 years ) in viral pathogenesis, treatment for prevention (microbicides, pre- and post-exposure prophylaxis) and vaccine immunology using non-human primate (NHP) models of human viral infections, particularly through its contribution to the development of NHP model of human HIV infection and AIDS. DIV has developed new programs on infection of NHP with human disesases: Flu, chikungunya virus, dengue virus, malaria, treponema infection and tuberculosis. Since 2008, the division is organized into a research group (Laboratory of anti-viral immunity) focused on pathogens/host interactions, pathogenesis and characterisation of immune responses in NHP, and core facilities dedicated to pre-clinical studies of innovative preventive and therapeutic strategies to cure infectious diseases (Laboratory of prevention of infectious diseases and innovative therapies) including vaccines and microbicides.


The Vita-Salute San Raffaele University (USR) is one of the few Italian universities in biomedical research where there is a tight interaction between basic and clinical research units, hospital divisions and teaching. Thanks to public and private investments, USR is highly committed to basic research and to transfer the important results found in new diagnostic tools or therapies. The ‘Vita-Salute’ San Raffaele University Medical School is the toprated Medical School in Italy. It is intimately linked to the Fondazione Centro San Raffaele del Monte Tabor, which comprises the Departments of Biology and Technology Research (DIBIT-1 and DIBIT-2), devoted to basic science; a top-quality private, non-profit hospital (San Raffaele Hospital, 1300 beds); the San Raffaele Biomedical Science Park. The Fondazione Centro San Raffaele del Monte Tabor has always championed new approaches towards a “molecular medicine”, whereby basic researchers, clinical investigators and physicians operate together to translate basic research into medical practice. Among the Italian Research Institutes, the San Raffaele Institute is ranked n.1 in funding by all European and National Agencies. The DIBIT is a 12.000 m2 building recently expanded by an additional 24.000 m2 of brand new facilities (DIBIT-2) and providing laboratory space for ~500 scientists and an efficiently organized network of scientific and technological resources that are able to support research and development in the biotechnological and bio-medical areas.


Seprox Biotech is a Spanish Biotech Company, born in December 2008, which has developed a unique production process based on chemical and enzymatic methods to produce polyphenols, some of the most potent natural antioxidants. One of those polyphenols is Hydroxytyrosol, that was previously obtained from the Olive, reaching purity levels substantially below those obtained by SEPROX BIOTECH (above 99,5%). These levels of purity and reproducibility make it suitable for being used in cosmetic, pharmacy, nutrition and food preservation. The main activity during these years has been the research and development of new products based on those polyphenols, and especially Hydroxytyrosol. Several projects, regarding to the food industry, cosmetics and human health have been carried out. Seprox Biotech has developed a previous project regarding to the demonstration of Hydroxytyrosol as a HIV integrase blocking agent, tested in humanised rabbit vaginas and obtaining very promising results.

Seprox has nowadays 7 people working in the company, most of them with University and Master Degrees, both in science and business. They also have a solid experience in research and product development in the pharmaceutical industry.

NEWS 01  


Productive HIV-1 infection of human cervical tissue ex vivo is associated with the secretory phase of menstrual cycle. Read more.    




10/01/2014. The partners of the project and the Scientific Advisory Board attended the Progress Meeting of the project in Madrid.  



October 7-10, 2013. ISCIII and SEPROX presented an oral communication and a poster in the AIDS Vaccine Conference. Read more.


Instituto de Salud Carlos III. 2013. All rights reserved

This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 305938.

Web Map  Legal AdviceAccesibility | Contact

cea unisr seprox biotech IscIII